- PLN296.08m
- PLN281.70m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.81 | ||
| Price to Tang. Book | 20.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.7% | ||
| Return on Equity | -142.81% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | n/a | 0 | 0.01 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- August 13th, 2018
- Public Since
- November 8th, 2021
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 4,129,468
- Address
- ul. Bierutowska 57-59, bud. III, WROCLAW, 51-317
- Web
- https://bioceltix.com/
- Phone
- +48 718808771
- Auditors
- 4AUDYT Sp. z o.o.
Upcoming Events for BCX
Similar to BCX
Biogened SA
Warsaw Stock Exchange
BioMaxima SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Celon Pharma SA
Warsaw Stock Exchange
Cosma SA
Warsaw Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in Bioceltix SA are trading at PLN71.70. This share price information is delayed by 15 minutes.
Shares in Bioceltix SA last closed at PLN71.70 and the price had moved by +28.04% over the past 365 days. In terms of relative price strength the Bioceltix SA share price has outperformed the FTSE Global All Cap Index by +18.1% over the past year.
There is no consensus recommendation for this security.
Bioceltix SA does not currently pay a dividend.
Bioceltix SA does not currently pay a dividend.
Bioceltix SA does not currently pay a dividend.
To buy shares in Bioceltix SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN71.70, shares in Bioceltix SA had a market capitalisation of PLN296.08m.
Here are the trading details for Bioceltix SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: BCX
Based on an overall assessment of its quality, value and momentum Bioceltix SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioceltix SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +1.34%.
As of the last closing price of PLN71.70, shares in Bioceltix SA were trading -6.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioceltix SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN71.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Bioceltix SA's directors